Fed. Circ. Won't Rethink Lymphoma, Myeloma Drug IP Revival
The Federal Circuit refused Thursday to reconsider a decision that a patent for a Millennium Pharmaceuticals Inc. drug effective against certain kinds of lymphoma and myeloma was wrongly deemed invalid as...To view the full article, register now.
Already a subscriber? Click here to view full article